‘Live Long and Prosper’: Nimoy-Knight Foundation Selects C2N’s CEO and Co-Founder for Prestigious Award Following Alzheimer’s Disease Blood Test FDA Clearance
Dr. Joel Braunstein Accepts Award on Behalf of C2N Team
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
The CEO and co-founder of C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, has accepted another honor on behalf of his team to cap a month-long series of significant achievements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917344529/en/
Dr. Braunstein wearing the Live Long & Prosper Tribute Award Pendant.
The Nimoy-Knight Foundation, which celebrates “Star Trek” actor and director Leonard Nimoy’s legacy of hope, inspiration, and compassion for all, chose Dr. Joel Braunstein for its Live Long & Prosper Tribute Award. The award honors “individuals and organizations that embody the spirit of Leonard Nimoy’s message of hope, logic, and service to others.”
The recognition follows C2N’s announcement in late August that the U.S. Food & Drug Administration has cleared C2N’s PrecivityAD2® test, the first Alzheimer’s blood test for adults with cognitive symptoms as young as 40.
Dr. Braunstein says, “On behalf of C2N Diagnostics, I am honored to accept the Live Long & Prosper Tribute Award from the Nimoy-Knight Foundation. This award symbolizes the ingenuity, peace, and compassion that defined Leonard Nimoy’s remarkable life.
“Leonard Nimoy inspired the world through his many creative and artistic endeavors. As Spock on ‘Star Trek,’ his iconic character demonstrated that logic and compassion drive meaningful solutions to complex problems. In his final years, Leonard channeled that same spirit into raising awareness about COPD, the disease that sadly took his life — and into advocating for a principle central to C2N’s mission: early detection changes lives. Every day, our team at C2N Diagnostics carries that principle forward in the fight against Alzheimer’s disease. We are working to ensure that patients with memory concerns and their families have access to earlier, more accurate diagnosis when it matters most.
“Thank you, David Knight and Julie Nimoy, for recognizing the impact of our work at C2N. We will continue to lead with the values Leonard embodied — innovation in service of humanity and the belief that everyone deserves the chance to live long and prosper.”
Nimoy-Knight Foundation founder David Knight says, “Julie and I are thrilled to present Dr. Braunstein with our foundation’s highest honor, the LLAP Tribute Award! We applaud his leadership, dedication, and commitment to helping improve the lives of so many people through C2N’s exciting advancements in technology that aid in diagnosing Alzheimer’s disease.”
Dr. Braunstein received his M.D. with Highest Distinction from Northwestern University Medical School. Subsequently, he trained in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School, and was a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions.
Additionally, he completed an MBA with management and health policy focus and maintained an Assistant Professorship in Cardiology at Johns Hopkins University. In 2010, he was named a Distinguished Alumnus of Johns Hopkins University. Dr. Braunstein also currently serves on the Board of Advisors for the Chemistry Life Processes Department at Northwestern University.
About C2N Diagnostics, LLC
C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help health care researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 200 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, and Mayo Clinic Laboratories. Over 90,000 Precivity®-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation, Alzheimer’s Association and The Michael J. Fox Foundation. For more information, visit www.c2n.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260917344529/en/
Media gallery
